Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
Advanced Drug Delivery Reviews · 2026-06 · 233 · 115840
DOI: 10.1016/j.addr.2026.115840 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-06. Verfasst von M Olazábal-Morán und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villavicios…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Precision Medicine, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 266 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villaviciosa, Calle Tajo s/n, 28670, Villaviciosa de Odón, Madrid, España.
- Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villaviciosa, Calle Tajo s/n, 28670, Villaviciosa de Odón, Madrid, España. Electr…
Zitieren
APA
Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026). Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer. Advanced Drug Delivery Reviews, 233, 115840. https://doi.org/10.1016/j.addr.2026.115840
Vancouver
Olazábal-Morán M, Blázquez-Barbadillo C, Pérez-Izquierdo E, Muñoz-Silva M, Garrido A. Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer. Advanced Drug Delivery Reviews. 2026;233:115840. doi:10.1016/j.addr.2026.115840
BibTeX
@article{OlazbalMorn2026,
author = {Olazábal-Morán, M and Blázquez-Barbadillo, C and Pérez-Izquierdo, E and Muñoz-Silva, M and Garrido, A},
title = {Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {233},
pages = {115840},
doi = {10.1016/j.addr.2026.115840}
}
EUVIMED